Further, given the recent approval of the translation inhibitor, paromomycin as a treatment against leishmaniasis [39] the differential sensitivities of L. major lines, expressing distinct RACK1 orthologs, to the specific translation inhibitors used in our studies, suggest RACK1 proteins as potential species-specific targets for parasite-selective therapies. The gene discussed is RACK1; the disease is leishmaniasis.